Vudalimab
Product Specifications
UNSPSC Description
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation[1].
Target Antigen
CTLA-4; PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/vudalimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Vudalimab]
References & Citations
[1]Hedvat M, et, al. Dual Blockade of PD1 and CTLA4 with Bispecific Antibody XmAb20717 Promotes Human T Cell Activation and Proliferation.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99166/Vudalimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99166/Vudalimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
2329669-72-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Rabbit Polyclonal SPRED2 Antibody [DyLight 650]](https://cdn.genprice.uk/genprice/genprice2.png)
MBS1003366-01 0.02 mg (E-Coli)
Recombinant Fremyella diplosiphon C-phycoerythrin beta chain (cpeB)
Ask
View Details MBS1003366-02 0.1 mg (E-Coli)
Recombinant Fremyella diplosiphon C-phycoerythrin beta chain (cpeB)
Ask
View Details 
MBS1003366-03 0.02 mg (Yeast)
Recombinant Fremyella diplosiphon C-phycoerythrin beta chain (cpeB)
Ask
View Details MBS1003366-04 0.1 mg (Yeast)
Recombinant Fremyella diplosiphon C-phycoerythrin beta chain (cpeB)
Ask
View Details MBS1003366-05 0.02 mg (Baculovirus)
Recombinant Fremyella diplosiphon C-phycoerythrin beta chain (cpeB)
Ask
View Details